Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

被引：2
|
作者：
Tanioka, M.
Fan, C.
Carey, L. A.
Hyslop, T.
Pitcher, B. N.
Parker, J. A.
Hoadley, K. A.
Henry, N. L.
Tolaney, S.
Dang, C.
Krop, I. E.
Harris, L.
Berry, D. A.
Mardis, E.
Perou, C. M.
Winer, E. P.
Hudis, C. A.
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[6] NCI, Bethesda, MD 20892 USA
[7] Alliance Stat & Data Ctr MD Anderson, Houston, TX USA
[8] Washington Univ, St Louis, MO USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-S3-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S3-05
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance).
    Golshan, Mehra
    Cirrincione, Constance T.
    Carey, Lisa A.
    Sikov, William M.
    Berry, Donald A.
    Burstein, Harold J.
    Overmoyer, Beth
    Henry, Norah Lynn
    Somlo, George
    Port, Elisa R.
    Winer, Eric P.
    Hudis, Clifford A.
    Ollila, David W.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
    Baselga, J.
    Manikhas, A.
    Cortes, J.
    Llombart, A.
    Roman, L.
    Semiglazov, V. F.
    Byakhov, M.
    Lokanatha, D.
    Forenza, S.
    Goldfarb, R. H.
    Matera, J.
    Azarnia, N.
    Hudis, C. A.
    Rozencweig, M.
    ANNALS OF ONCOLOGY, 2014, 25 (03) : 592 - 598
  • [23] A Phase II Preoperative Trial of Concurrent Trastuzumab and Paclitaxel without Anthracycline in HER2-Positive Operable Breast Cancer
    Sato, T.
    Hayashida, T.
    Takahashi, M.
    Sakata, M.
    Jinno, H.
    Hirose, S.
    Mukai, M.
    Kitagawa, Y.
    CANCER RESEARCH, 2010, 70
  • [24] Surgical aspect in NOAH Phase III trial (neoadjuvant trastuzumab in HER2-positive locally advanced breast cancer)
    Semiglazov, V.
    Eiermann, W.
    Manikhas, A.
    Bozok, A.
    Lluch, A.
    Tjulandine, S.
    Feyereislova, A.
    Valagussae, P.
    Baselga, J.
    Gianni, L.
    EJC SUPPLEMENTS, 2008, 6 (07): : 169 - 170
  • [25] Phase II Trial of Neoadjuvant Pegylated Liposomal Doxorubicin with Paclitaxel and Trastuzumab in Patients with Operable Her2-Positive Breast Cancer
    Hyams, D. M.
    Leichman, G. C.
    Klein, P.
    Rietchsel, P.
    Levine, E. G.
    Gebski, V. J.
    Kelley, M. A.
    CANCER RESEARCH, 2009, 69 (24) : 570S - 570S
  • [26] A phase III randomized study of Paclitaxel and Trastuzumab versus Paclitaxel, Trastuzumab and Lapatinib in first line treatment of HER2 positive metastatic breast cancer.
    Crown, J. P.
    Moulton, B.
    O'Donovan, N.
    CANCER RESEARCH, 2012, 72
  • [27] De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab in HER2-positive early breast cancer (HELEN-006):a randomized,phase 3 trial
    Liu, Zhenzhen
    Chen, Xiuchun
    Qiao, Jianghua
    Jiao Dechuang
    Wang, Chengzheng
    Sun, Xianfu
    Lu, Zhenduo
    Li, Lianfang
    Zhang, Chongjian
    Yan, Min
    Wei, Ya
    Bo, Chen
    Feng, Yueqing
    Deng, Miao
    Ma, Mingde
    CANCER RESEARCH, 2024, 84 (09)
  • [28] The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis
    Chen, Zhe-Ling
    Shen, Yan-Wei
    Li, Shu-Ting
    Li, Chun-Li
    Zhang, Ling-Xiao
    Yang, Jiao
    Lv, Meng
    Lin, Ya-Yun
    Wang, Xin
    Yang, Jin
    ONCOTARGETS AND THERAPY, 2016, 9 : 3233 - 3247
  • [29] TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
    Rimawi, Mothaffar F.
    Niravath, Polly
    Wang, Tao
    Rexer, Brent N.
    Forero, Andres
    Wolff, Antonio C.
    Nanda, Rita
    Storniolo, Anna M.
    Krop, Ian
    Goetz, Matthew P.
    Nangia, Julie R.
    Jiralerspong, Sao
    Pavlick, Anne
    Veeraraghavan, Jamunarani
    De Angelis, Carmine
    Gutierrez, Carolina
    Schiff, Rachel
    Hilsenbeck, Susan G.
    Osborne, C. Kent
    CLINICAL CANCER RESEARCH, 2020, 26 (04) : 821 - 827
  • [30] Analysis of αβ and γδ circulating T cells in the PHERGain randomized phase 2 trial for patients with HER2-positive early breast cancer receiving neoadjuvant trastuzumab and pertuzumab without chemotherapy: LINGain
    Andreu-Ballester, Juan Carlos
    Perez-Garcia, Jose Manuel
    Bermejo, Begona
    Caranana, Vicente
    Iranzo, Vega
    Gavila, Joaquin
    Santaballa, Ana
    Gomez-Soler, Maria Carmen
    Sampayo-Cordero, Miguel
    Malfettone, Andrea
    Cortes, Javier
    Llombart-Cussac, Antonio
    CANCER RESEARCH, 2022, 82 (04)
12345